Bial Portela &

Company snapshot

Bial Portela & is a pharma organization headquartered in EU. Primary therapeutic focus areas include Chronic obstructive pulmonary disease (COPD), Partial Epilepsy in Children and Adolescents, Intermediate and high-risk prostate cancer, papillary thyroid carcinoma, idiopathic infertility. NovaPharmaNews links 7 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (5), phase 2 (1), phase 1 (1).

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 US patent(s) indexed to this assignee profile.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Bial Portela &. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Bial Portela &.

1. Jun 8, 2026 Clinical update

   BIA-28-6156-111 — Phase 1

2. Jun 8, 2026 Clinical update

   2021/ABM/01/00010 — Phase 3

3. Jun 8, 2026 Clinical update

   2019/ABM/01/00074 — Phase 3

4. Jun 8, 2026 Clinical update

   Placebo, GLUCOPHAGE 500 mg tabletki powlekane — Phase 2

5. Jun 8, 2026 Clinical update

   GLUCOPHAGE 500 mg tabletki powlekane, Placebo — Phase 3

View all clinical trial activity →

• What is Bial Portela &?

  Bial Portela & is a pharma organization headquartered in EU. Primary therapeutic focus areas include Chronic obstructive pulmonary disease (COPD), Partial Epilepsy in Children and Adolescents, Intermediate and high-risk prostate cancer, papillary thyroid carcinoma, idiopathic inf

• Is Bial Portela & publicly traded?

  Bial Portela & appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Bial Portela & develop or market?

  We link 7 drug profile(s) where Bial Portela & is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/bial-portela-companhia-s-a#company-drugs.

• What are the latest developments for Bial Portela &?

  In the last 12 months our linked public records show 7 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Bial Portela & focus on?

  Bial Portela & focuses on Chronic obstructive pulmonary disease (COPD), Partial Epilepsy in Children and Adolescents, Intermediate and high-risk prostate cancer based on our analysis of their pipeline programs and drug development activities.